A growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism , placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape. A new review highlights how this key metabolic regulator is emerging as a critical driver of tumor development and a promising focus for future cancer therapies .
Cancer cells depend on extensive metabolic changes to sustain rapid growth and survival. Among these changes, disruptions in cholesterol biosynthesis have gained increasing attention. The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) plays a central role in this process, acting as the rate-limiting step in the production of cholesterol, a molecule essential for cell membrane integrity and signaling pathways .
Elevated levels of HMGCR have been consistently observed across multiple cancer types, including breast, liver, prostate, and colorectal cancers. This upregulation supports tumor growth by enhancing cell proliferation , enabling metastasis , and helping cancer cells evade programmed cell death . The enzyme also contributes to the reprogramming of cellular metabolism, allowing tumors to adapt to stressful conditions such as low oxygen and nutrient scarcity.
Beyond its biological significance, HMGCR is gaining recognition as a compelling therapeutic target . Inhibiting its activity can disrupt the supply of cholesterol and related molecules that tumors rely on, leading to reduced tumor growth and increased sensitivity to treatment. Compounds that target HMGCR , including widely used cholesterol-lowering drugs, are being explored for their potential to enhance anti-cancer strategies, either alone or in combination with other treatments .
The review also underscores the enzyme’s involvement in major oncogenic signaling pathways , including those that regulate cell survival, immune evasion, and tumor progression. By influencing pathways such as PI3K/AKT/mTOR and immune checkpoint regulation, HMGCR sits at a critical intersection between metabolism and cancer signaling, reinforcing its importance in modern oncology.
Despite its promise, challenges remain. Tumors can develop adaptive mechanisms that reduce the effectiveness of HMGCR-targeted therapies , and potential side effects must be carefully managed. Nonetheless, advances in precision medicine, combination therapies, and biomarker-driven approaches are helping to address these limitations.
Overall, the findings position HMGCR as more than a metabolic enzyme—it is a central regulator of tumor behavior and a key opportunity for innovation in precision oncology . As research continues to refine strategies for targeting metabolic pathways, HMGCR may play a defining role in the next generation of cancer treatments.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 | Impact Factor: 14.6
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/ Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/ All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820 eISSN: 2352-3042 CN: 50-1221/R Contact Us: editor@genesndiseases.cn X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
Reference
Wenfang Li, Jianxiong Xu, Yuxuan Long, Han Zhang, Xiaojuan Rong, Zhengding Su, Emerging roles of the metabolic regulator 3-hydroxy-3-methylglutaryl coenzyme-CoA reductase in human cancers: From biology to therapeutics, Genes & Diseases, Volume 13, Issue 4, 2026, 101945, https://doi.org/10.1016/j.gendis.2025.101945
Funding
National Natural Science Foundation of China 32471260
National Natural Science Foundation of China 82460809
Tianshan Talent Training Program (Xinjiang, China) 2023TSYCCX0065
Genes & Diseases